Adjudicating bleeding events in a platelet dose study: Impact on outcome results and challenges

Transfusion

Volumn 51, Issue 11, 2011, Pages 2304-2310

  Heddle, Nancy M ^{a,b,c,d,e,f,g,h}   Wu, Cynthia ^{a,b,c,d,e,f,g,h}   Vassallo, Ralph ^{a,b,c,d,e,f,g,h}   Carey, Patricia ^{a,b,c,d,e,f,g,h}   Arnold, Donald ^{a,b,c,d,e,f,g,h}   Lozano, Miguel ^{a,b,c,d,e,f,g,h}   Pavenski, Katerina ^{a,b,c,d,e,f,g,h}   Sweeney, Joseph ^{a,b,c,d,e,f,g,h}   Stanworth, Simon ^{a,b,c,d,e,f,g,h}   Liu, Yang ^{a,b,c,d,e,f,g,h}   Traore, Aicha ^{a,b,c,d,e,f,g,h}   Barty, Rebecca ^{a,b,c,d,e,f,g,h}   Tinmouth, Alan ^{a,b,c,d,e,f,g,h}  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c Penn Jersey Region   (United States)

^d UNIVERSITY OF CINCINNATI ACADEMIC HEALTH CENTER   (United States)

^e HOSPITAL CLÍNIC   (Spain)

^f BROWN UNIVERSITY   (United States)

^g NHS BLOOD AND TRANSPLANT   (United Kingdom)

^h OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLEEDING; BLOOD CELL COUNT; BLOOD TRANSFUSION; CLINICAL ASSESSMENT; CONSENSUS DEVELOPMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; POINT OF CARE TESTING;

HEMORRHAGE; HUMANS; PLATELET TRANSFUSION; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 80054991804     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03181.x     Document Type: Article

References (22)

1. Heddle NM, Arnold DM, Webert KE,. Time to rethink clinically important outcomes in platelet transfusion trials. Transfusion 2011; 51: 430-4.
2. Rebulla P, Finazzi G, Marangoni F, Avvisati G, Gugliotta L, Tognoni G, Barbui T, Mandelli F, Sirchia G,. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dellAdulto. N Engl J Med 1997; 337: 1870-5.
3. Tinmouth A, Tannock IF, Crump M, Tomlinson G, Brandwein J, Minden M, Sutton D,. Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design. Transfusion 2004; 44: 1711-9. (Pubitemid 39644055)
4. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, Stadtmauer EA, Lopez-Plaza I, Coutre S, Strauss RG, Goodnough LT, Fridey JL, Raife T, Cable R, Murphy S, Howard F 4th, Davis K, Lin JS, Metzel P, Corash L, Koutsoukos A, Lin L, Buchholz DH, Conlan MG,. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 2004; 104: 1534-41. (Pubitemid 39166535)
5. Heddle NM, Cook RJ, Tinmouth A, Kouroukis CT, Hervig T, Klapper E, Brandwein JM, Szczepiorkowski ZM, AuBuchon JP, Barty RL, Lee KA, SToP Study Investigators of the BEST Collaborative. A randomized controlled trial comparing standard- and low-dose strategies for transfusion of platelets (SToP) to patients with thrombocytopenia. Blood 2009; 113: 1564-73.
6. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus LC, de Greef GE, Luten M, Huijgens PC, Brand A, van Rhenen DJ, Dutch-Belgian HOVON Cooperative Group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
7. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD, Konkle BA, Woodson RD, Ortel TL, Hillyer CD, Skerrett DL, McCrae KR, Sloan SR, Uhl L, George JN, Aquino VM, Manno CS, McFarland JG, Hess JR, Leissinger C, Granger S,. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.
8. Miller AB, Hoogstraten B, Staquet M, Winkler A,. Reporting results of cancer treatment. Cancer 1981; 47: 207-14. (Pubitemid 11167383)
9. Heddle NM, Cook RJ, Webert KE, Sigouin C, Rebulla P,. Methodologic issues in the use of bleeding as an outcome in transfusion medicine studies. Transfusion 2003; 43: 742-52. (Pubitemid 36629119)
10. Stanworth SJ, Dyer C, Casbard A, Murphy MF,. Feasibility and usefulness of self-assessment of bleeding in patients with haematological malignancies, and the association between platelet count and bleeding. Vox Sang 2006; 91: 63-9. (Pubitemid 43822306)
11. Webert KE, Cook RJ, Couban S, Carruthers J, Heddle NM,. A study of the agreement between patient self-assessment and study personnel assessment of bleeding symptoms. Transfusion 2006; 46: 1926-33. (Pubitemid 44631600)
12. Cook D, Walter S, Freitag A, Guyatt G, Devitt H, Meade M, Griffith L, Sarabia A, Fuller H, Turner M, Gough K,. Adjudicating ventilator-associated pneumonia in a randomized trial of critically ill patients. J Crit Care 1998; 13: 159-63. (Pubitemid 29015270)
13. Walter SD, Cook DJ, Guyatt GH, King D, Troyan S,. Outcome assessment for clinical trials: how many adjudicators do we need? Canadian Lung Oncology Group1. Control Clin Trials 1997; 18: 27-42. (Pubitemid 27145445)
14. Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, Lawrence M, Neal B, Reidies H, Santarelli L, Schroyer R, Stockbridge NL, Feng Z,. Do we need to adjudicate major clinical events? Clin Trials 2008; 5: 56-60. (Pubitemid 351412373)
15. Meinert CL, Martin BK, McCaffrey LD, Breitner JC,. Do we need to adjudicate major clinical events? Clin Trials 2008; 5: 557.
16. Naslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, Wallentin L,. The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committees final decision on end-points. Eur Heart J 1999; 20: 771-7. (Pubitemid 29209911)
17. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S, WHI Morbidity and Mortality Committee. Outcomes ascertainment and adjudication methods in the Womens Health Initiative. Ann Epidemiol 2003; 13 (9 Suppl): S122-8. (Pubitemid 37324181)
18. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, Crenshaw BS, Tardiff BE, Granger CB, DeJong I, Bhapkar M, Widimsky P, Corbalon R, Lee KL, Deckers JW, Simoons ML, Topol EJ, Califf RM, for the PURSUIT Investigators. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2001; 2: 187-94. (Pubitemid 32780806)
19. Peterson JL, Haque G, Hellkamp AS, Flaker GC, Mark Estes NA 3rd, Marchlinski FE, McAnulty JH, Greenspon AJ, Marinchak RA, Lee KL, Lamas GA, Mahaffey KW, MOST Clinical Events Committee. Comparing classifications of death in the mode selection trial: agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials 2006; 27: 260-8.
20. Pogue J, Walter SD, Yusuf S,. Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 2009; 6: 239-51.
21. Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J,. Lessons learned from independent central review. Eur J Cancer 2009; 45: 268-74.
22. Webert KE, Arnold E, Barty R, Traore A, Arnold DM, Heddle NM,. The development of a bleeding severity measurement scale (BSMS): a new measurement tool [abstract]. Transfusion 2009; 49 (3S): 165A.